GlassScriptPhysician profile
Christopher C Mai
NPI 1518957596
$2,272.31
in general payments reported to CMS, 2019-2025
28 companies · $82.22 in 2025
The $82.22 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $686 · 2021: $567 · 2022: $473 · 2023: $31.34 · 2025: $82.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $828.25 | 2019-2022 | |
| Amgen INC. | $203.97 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $170.46 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $157.30 | 2019-2025 | Farxiga |
| Amarin Pharma, INC. | $138.77 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $129.21 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $67.00 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $63.61 | 2019-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $45.96 | 2021-2022 | |
| Daiichi Sankyo INC. | $45.28 | 2019-2022 | |
| Vifor Pharma, INC. | $44.08 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $40.76 | 2021 | |
| Aurinia Pharma U.S., INC. | $39.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.95 | 2021-2022 | |
| Baxter Healthcare | $28.78 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.14 | 2021 | |
| Esperion Therapeutics, INC. | $24.88 | 2021 | |
| Lilly USA, LLC | $23.92 | 2020 | |
| Travere Therapeutics, INC. | $20.96 | 2022 | |
| Novo Nordisk INC | $19.28 | 2022 | |
| Genzyme Corporation | $17.15 | 2022 | |
| Allergan, INC. | $16.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.49 | 2019 | |
| Shire North American Group INC | $14.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.94 | 2020 | |
| Fresenius USA Marketing, INC. | $12.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.